Published: 28 March 2023
Author(s): Javier López Robles, Alberto Carmona-Bayonas, Paula Jiménez-Fonseca
Issue: June 2023
Section: Commentary

Predicting the risk of rethrombosis and hemorrhage in cancer patients with venous thromboembolism (VTE) poses a considerable challenge. The wide range of individual differences in this population makes both complications critical milestones during the ‘cancer journey’ [1]. Low molecular weight heparin (LMWH) was once the single established treatment for cancer-associated thrombosis. Nonetheless, direct oral anticoagulants (DOACs) have emerged as a promising alternative that simplifies therapy. Although the risk of recurrent thrombosis or major bleeding in patients is undeniably linked to unpredictable and unquantifiable events, like missed doses, temporary treatment interruption for an endoscopy, unintended telangiectasia rupture, etc., these factors do not impede the broader modeling of these endpoints to achieve a thorough understanding.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness